Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Exosomal microRNAs: A Diagnostic and Therapeutic Small Bio-molecule in Esophageal Cancer

Author(s): Mahshid Shahverdi and Maryam Darvish*

Volume 23, Issue 4, 2023

Published on: 06 July, 2022

Page: [312 - 323] Pages: 12

DOI: 10.2174/1566524022666220321125134

Price: $65

conference banner
Abstract

Esophageal cancer (EC) is one of the major causes of cancer-related death worldwide. EC is usually diagnosed at a late stage, and despite aggressive therapy, the five-year survival rate of patients remains poor. Exosomes play important roles in cancer biology. Indeed, exosomes are implicated in tumor proliferation, angiogenesis, and invasion. They contain bioactive molecules such as lipids, proteins, and non-coding RNAs. Exosome research has recently concentrated on microRNAs, which are tiny noncoding endogenous RNAs that can alter gene expression and are linked to nearly all physiological and pathological processes, including cancer. It is suggested that deregulation of miRNAs results in cancer progression and directly induces tumor initiation. In esophageal cancer, miRNA dysregulation plays an important role in cancer prognosis and patients’ responsiveness to therapy, indicating that miRNAs are important in tumorigenesis. In this review, we summarize the impact of exosomal miRNAs on esophageal cancer pathogenesis and their potential applications for EC diagnosis and therapy.

Keywords: Exosomes, miRNA, exosomal microRNA, esophageal cancer, therapeutic biomolecule, diagnostic biomolecule, bioactive molecules.

« Previous Next »
[1]
D’Journo XB, Thomas PA. Current management of esophageal cancer. J Thorac Dis 2014; 6 (Suppl. 2): S253-64.
[PMID: 24868443]
[2]
Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol 2015; 21(26): 7933-43.
[http://dx.doi.org/10.3748/wjg.v21.i26.7933] [PMID: 26185366]
[3]
Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. J Surg Oncol 2017; 115(5): 564-79.
[http://dx.doi.org/10.1002/jso.24592] [PMID: 28320055]
[4]
Napier KJ, Scheerer M, Misra S. Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 2014; 6(5): 112-20.
[http://dx.doi.org/10.4251/wjgo.v6.i5.112] [PMID: 24834141]
[5]
Ashrafizadeh M, Bakhoda MR, Bahmanpour Z, et al. Apigenin as tumor suppressor in cancers: Biotherapeutic activity, nanodelivery, and mechanisms with emphasis on pancreatic cancer. Front Chem 2020; 8: 829.
[http://dx.doi.org/10.3389/fchem.2020.00829] [PMID: 33195038]
[6]
Pourhanifeh MH, Darvish M, Tabatabaeian J, et al. Therapeutic role of curcumin and its novel formulations in gynecological cancers. J Ovarian Res 2020; 13(1): 130.
[http://dx.doi.org/10.1186/s13048-020-00731-7] [PMID: 33148295]
[7]
Sohda M, Kuwano H. Current status and future prospects for esophageal cancer treatment. Ann Thorac Cardiovasc Surg 2017; 23(1): 1-11.
[http://dx.doi.org/10.5761/atcs.ra.16-00162] [PMID: 28003586]
[8]
Gao DC, Hou B, Zhou D, et al. Tumor-derived exosomal miR-103a-2-5p facilitates esophageal squamous cell carcinoma cell proliferation and migration. Eur Rev Med Pharmacol Sci 2020; 24(11): 6097-110.
[PMID: 32572925]
[9]
Chawla JPS, Iyer N, Soodan KS, Sharma A, Khurana SK, Priyadarshni P. Role of miRNA in cancer diagnosis, prognosis, therapy and regulation of its expression by Epstein-Barr virus and human papillomaviruses: With special reference to oral cancer. Oral Oncol 2015; 51(8): 731-7.
[http://dx.doi.org/10.1016/j.oraloncology.2015.05.008] [PMID: 26093389]
[10]
Sadri Nahand J, Rabiei N, Fathazam R, et al. Oncogenic viruses and chemoresistance: What do we know? Pharmacol Res 2021; 170: 105730.
[http://dx.doi.org/10.1016/j.phrs.2021.105730] [PMID: 34119621]
[11]
Tanaka Y, Kamohara H, Kinoshita K, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 2013; 119(6): 1159-67.
[http://dx.doi.org/10.1002/cncr.27895] [PMID: 23224754]
[12]
Warnecke-Eberz U, Chon SH, Hölscher AH, Drebber U, Bollschweiler E. Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor. Tumour Biol 2015; 36(6): 4643-53.
[http://dx.doi.org/10.1007/s13277-015-3112-0] [PMID: 25631748]
[13]
Liao J, Liu R, Shi YJ, Yin LH, Pu YP. Exosome-shuttling microRNA-21 promotes cell migration and invasion-targeting PDCD4 in esophageal cancer. Int J Oncol 2016; 48(6): 2567-79.
[http://dx.doi.org/10.3892/ijo.2016.3453] [PMID: 27035745]
[14]
Oliveto S, Mancino M, Manfrini N, Biffo S. Role of microRNAs in translation regulation and cancer. World J Biol Chem 2017; 8(1): 45-56.
[http://dx.doi.org/10.4331/wjbc.v8.i1.45] [PMID: 28289518]
[15]
Maltby S, Plank M, Tay HL, Collison A, Foster PS. Targeting microRNA function in respiratory diseases: mini-review. Front Physiol 2016; 7: 21.
[http://dx.doi.org/10.3389/fphys.2016.00021] [PMID: 26869937]
[16]
Clark RJ, Craig MP, Agrawal S, Kadakia M. microRNA involvement in the onset and progression of Barrett’s esophagus: A systematic review. Oncotarget 2018; 9(8): 8179-96.
[http://dx.doi.org/10.18632/oncotarget.24145] [PMID: 29487725]
[17]
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne) 2018; 9: 402.
[http://dx.doi.org/10.3389/fendo.2018.00402] [PMID: 30123182]
[18]
Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal 2015; 8(368): re3-3.
[http://dx.doi.org/10.1126/scisignal.2005825] [PMID: 25783160]
[19]
Rajagopal C, Harikumar KB. The origin and functions of exosomes in cancer. Front Oncol 2018; 8: 66.
[http://dx.doi.org/10.3389/fonc.2018.00066] [PMID: 29616188]
[20]
Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol 2016; 51(3): 121-34.
[http://dx.doi.org/10.3109/10409238.2015.1117054] [PMID: 26628006]
[21]
Gurtner A, Falcone E, Garibaldi F, Piaggio G. Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res 2016; 35(1): 45.
[http://dx.doi.org/10.1186/s13046-016-0319-x] [PMID: 26971015]
[22]
Reddy KB. MicroRNA (miRNA) in cancer. Cancer Cell Int 2015; 15(1): 38.
[http://dx.doi.org/10.1186/s12935-015-0185-1] [PMID: 25960691]
[23]
Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci 2010; 101(11): 2309-15.
[http://dx.doi.org/10.1111/j.1349-7006.2010.01683.x] [PMID: 20726859]
[24]
Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4(3): 143-59.
[http://dx.doi.org/10.1002/emmm.201100209] [PMID: 22351564]
[25]
Chen B, Li H, Zeng X, et al. Roles of microRNA on cancer cell metabolism. J Transl Med 2012; 10(1): 228.
[http://dx.doi.org/10.1186/1479-5876-10-228] [PMID: 23164426]
[26]
Wang Y, Lee CG. MicroRNA and cancer--focus on apoptosis. J Cell Mol Med 2009; 13(1): 12-23.
[http://dx.doi.org/10.1111/j.1582-4934.2008.00510.x] [PMID: 19175697]
[27]
Hemmatzadeh M, Mohammadi H, Karimi M, Musavishenas MH, Baradaran B. Differential role of microRNAs in the pathogenesis and treatment of Esophageal cancer. Biomed Pharmacother 2016; 82: 509-19.
[http://dx.doi.org/10.1016/j.biopha.2016.05.009] [PMID: 27470391]
[28]
Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135(2): 255-60.
[http://dx.doi.org/10.1016/j.jtcvs.2007.08.055] [PMID: 18242245]
[29]
Liu S-G, Qin XG, Zhao BS, et al. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett 2013; 5(5): 1639-42.
[http://dx.doi.org/10.3892/ol.2013.1251] [PMID: 23761828]
[30]
Lin Z-X, Lin X, Zhu L, et al. MiR-195-5p reduces esophageal cancer cell proliferation through the IGF-1R/AKT axis. Res Squ. 2021.
[http://dx.doi.org/10.21203/rs.3.rs-569371/v1]
[31]
Song Q, Liu H, Li C, Liang H. miR-33a-5p inhibits the progression of esophageal cancer through the DKK1-mediated Wnt/β-catenin pathway. Aging (Albany NY) 2021; 13(16): 20481-94.
[http://dx.doi.org/10.18632/aging.203430] [PMID: 34426559]
[32]
Phatak P, Noe M, Asrani K, Chesnick IE, Greenwald BD, Donahue JM. MicroRNA-141-3p regulates cellular proliferation, migration, and invasion in esophageal cancer by targeting tuberous sclerosis complex 1. Mol Carcinog 2021; 60(2): 125-37.
[http://dx.doi.org/10.1002/mc.23274] [PMID: 33382472]
[33]
Yao W, Jia X, Xu L, Li S, Wei L. MicroRNA-2053 involves in the progression of esophageal cancer by targeting KIF3C. Cell Cycle 2021; 20(12): 1163-72.
[http://dx.doi.org/10.1080/15384101.2021.1929675] [PMID: 34057012]
[34]
Rai GP, Baird SK. Tissue inhibitor of matrix metalloproteinase-3 has both anti-metastatic and anti-tumourigenic properties. Clin Exp Metastasis 2020; 37(1): 69-76.
[http://dx.doi.org/10.1007/s10585-019-10017-y] [PMID: 31894441]
[35]
Strouhalova K, Přechová M, Gandalovičová A, Brábek J, Gregor M, Rosel D. Vimentin intermediate filaments as potential target for cancer treatment. Cancers (Basel) 2020; 12(1): 184.
[http://dx.doi.org/10.3390/cancers12010184] [PMID: 31940801]
[36]
Usman S, Waseem NH, Nguyen TKN, et al. Vimentin is at the heart of Epithelial Mesenchymal Transition (EMT) mediated metastasis. Cancers (Basel) 2021; 13(19): 4985.
[http://dx.doi.org/10.3390/cancers13194985] [PMID: 34638469]
[37]
Hu H-F, Xu WW, Zhang WX, et al. Identification of miR-515-3p and its targets, vimentin and MMP3, as a key regulatory mechanism in esophageal cancer metastasis: functional and clinical significance. Signal Transduct Target Ther 2020; 5(1): 271.
[http://dx.doi.org/10.1038/s41392-020-00275-8] [PMID: 33243974]
[38]
Yu Z, Ni F, Chen Y, Zhang J, Cai J, Shi W. miR-125b suppresses cell proliferation and metastasis by targeting HAX-1 in esophageal squamous cell carcinoma. Pathol Res Pract 2020; 216(2): 152792.
[http://dx.doi.org/10.1016/j.prp.2019.152792] [PMID: 31899048]
[39]
Tan X, Ren S, Fu MZ, et al. microRNA-196b promotes esophageal squamous cell carcinogenesis and chemoradioresistance by inhibiting EPHA7, thereby restoring EPHA2 activity. Am J Cancer Res 2021; 11(7): 3594-610.
[PMID: 34354862]
[40]
Zhu Y, Zhang Y, Li X, et al. Downregulation of miR 106b 3p increases sensitivity to cisplatin in esophageal cancer cells by targeting TGM3. Mol Med Rep 2021; 23(6): 1-7.
[http://dx.doi.org/10.3892/mmr.2021.12110]
[41]
Tian Y, Luo A, Cai Y, et al. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem 2010; 285(11): 7986-94.
[http://dx.doi.org/10.1074/jbc.M109.062877] [PMID: 20075075]
[42]
Du J, Zhang L. Analysis of salivary microRNA expression profiles and identification of novel biomarkers in esophageal cancer. Oncol Lett 2017; 14(2): 1387-94.
[http://dx.doi.org/10.3892/ol.2017.6328] [PMID: 28789354]
[43]
Hiyoshi Y, Kamohara H, Karashima R, et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009; 15(6): 1915-22.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-2545] [PMID: 19276261]
[44]
Mathé EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res 2009; 15(19): 6192-200.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-1467] [PMID: 19789312]
[45]
Kan T, Meltzer SJ. MicroRNAs in Barrett’s esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol 2009; 9(6): 727-32.
[http://dx.doi.org/10.1016/j.coph.2009.08.009] [PMID: 19773200]
[46]
Conlan RS, Pisano S, Oliveira MI, Ferrari M, Mendes Pinto I. Exosomes as reconfigurable therapeutic systems. Trends Mol Med 2017; 23(7): 636-50.
[http://dx.doi.org/10.1016/j.molmed.2017.05.003] [PMID: 28648185]
[47]
Kan T, Sato F, Ito T, et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009; 136(5): 1689-700.
[http://dx.doi.org/10.1053/j.gastro.2009.02.002] [PMID: 19422085]
[48]
Lee K-H, Goan YG, Hsiao M, et al. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res 2009; 315(15): 2529-38.
[http://dx.doi.org/10.1016/j.yexcr.2009.06.001] [PMID: 19501585]
[49]
Hu C, Lv L, Peng J, et al. MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expression. Oncol Lett 2017; 13(6): 4769-75.
[http://dx.doi.org/10.3892/ol.2017.6098] [PMID: 28599478]
[50]
Ogawa R, Ishiguro H, Kuwabara Y, et al. Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol 2009; 42(2): 102-9.
[http://dx.doi.org/10.1007/s00795-009-0443-1] [PMID: 19536617]
[51]
Chen ZL, Zhao XH, Wang JW, et al. microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem 2011; 286(12): 10725-34.
[http://dx.doi.org/10.1074/jbc.M110.165654] [PMID: 21148309]
[52]
Su H, Wu Y, Fang Y, et al. MicroRNA 301a targets WNT1 to suppress cell proliferation and migration and enhance radiosensitivity in esophageal cancer cells. Oncol Rep 2019; 41(1): 599-607.
[PMID: 30365079]
[53]
Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin 2017; 38(6): 754-63.
[http://dx.doi.org/10.1038/aps.2017.12] [PMID: 28392567]
[54]
Gurunathan S, Kang MH, Jeyaraj M, Qasim M, Kim JH. Review of the isolation, characterization, biological function, and multifarious therapeutic approaches of exosomes. Cells 2019; 8(4): 307.
[http://dx.doi.org/10.3390/cells8040307] [PMID: 30987213]
[55]
Ferguson SW, Nguyen J. Exosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity. J Control Release 2016; 228: 179-90.
[http://dx.doi.org/10.1016/j.jconrel.2016.02.037] [PMID: 26941033]
[56]
Darband SG, Mirza-Aghazadeh-Attari M, Kaviani M, et al. Exosomes: natural nanoparticles as bio shuttles for RNAi delivery. J Control Release 2018; 289: 158-70.
[http://dx.doi.org/10.1016/j.jconrel.2018.10.001] [PMID: 30290245]
[57]
Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol 2012; 3: 124.
[http://dx.doi.org/10.3389/fphys.2012.00124] [PMID: 22563321]
[58]
Ren J, He W, Zheng L, Duan H. From structures to functions: insights into exosomes as promising drug delivery vehicles. Biomater Sci 2016; 4(6): 910-21.
[http://dx.doi.org/10.1039/C5BM00583C] [PMID: 26977477]
[59]
Frydrychowicz M, Kolecka-Bednarczyk A, Madejczyk M, Yasar S, Dworacki G. Exosomes - structure, biogenesis and biological role in non-small-cell lung cancer. Scand J Immunol 2015; 81(1): 2-10.
[http://dx.doi.org/10.1111/sji.12247] [PMID: 25359529]
[60]
Tai YL, Chen KC, Hsieh JT, Shen TL. Exosomes in cancer development and clinical applications. Cancer Sci 2018; 109(8): 2364-74.
[http://dx.doi.org/10.1111/cas.13697] [PMID: 29908100]
[61]
Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: Trafficking, sorting, and function. Gen Proteom Bioinform 2015; 13(1): 17-24.
[http://dx.doi.org/10.1016/j.gpb.2015.02.001] [PMID: 25724326]
[62]
Bhome R, Del Vecchio F, Lee GH, et al. Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. Cancer Lett 2018; 420: 228-35.
[http://dx.doi.org/10.1016/j.canlet.2018.02.002] [PMID: 29425686]
[63]
Wong GL, Abu Jalboush S, Lo H-W. Exosomal microRNAs and organotropism in breast cancer metastasis. Cancers (Basel) 2020; 12(7): 1827.
[http://dx.doi.org/10.3390/cancers12071827] [PMID: 32646059]
[64]
Li J, Jiang X, Wang K. Exosomal miRNA: An alternative mediator of cell-to-cell communication. ExRNA 2019; 1(1): 31.
[http://dx.doi.org/10.1186/s41544-019-0025-x]
[65]
Schwarzenbach H. The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Rev Mol Diagn 2015; 15(9): 1159-69.
[http://dx.doi.org/10.1586/14737159.2015.1069183] [PMID: 26202667]
[66]
Dilsiz N. Role of exosomes and exosomal microRNAs in cancer. Future Sci OA 2020; 6(4): FSO465-5.
[http://dx.doi.org/10.2144/fsoa-2019-0116] [PMID: 32257377]
[67]
Vautrot V, Chanteloup G, Elmallah M, et al. Exosomal miRNA: Small molecules, big impact in colorectal cancer. J Oncol 2019; 2019: 8585276.
[http://dx.doi.org/10.1155/2019/8585276]
[68]
Thind A, Wilson C. Exosomal miRNAs as cancer biomarkers and therapeutic targets. J Extracell Vesicles 2016; 5(1): 31292.
[http://dx.doi.org/10.3402/jev.v5.31292] [PMID: 27440105]
[69]
Zeng X, Wang HY, Bai SY, Pu K, Wang YP, Zhou YN. The roles of microRNAs in multidrug-resistance mechanisms in gastric cancer. Curr Mol Med 2020; 20(9): 667-74.
[http://dx.doi.org/10.2174/1566524020666200226124336] [PMID: 32209033]
[70]
Kim DH, Park S, Kim H, et al. Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4. Cancer Lett 2020; 475: 2-13.
[http://dx.doi.org/10.1016/j.canlet.2020.01.023] [PMID: 32004570]
[71]
Du J, Liang Y, Li J, Zhao JM, Wang ZN, Lin XY. Gastric cancer cell-derived exosomal microRNA-23a promotes angiogenesis by targeting PTEN. Front Oncol 2020; 10: 326.
[http://dx.doi.org/10.3389/fonc.2020.00326] [PMID: 32232005]
[72]
Wang M, Yu F, Ding H, Wang Y, Li P, Wang K. Emerging function and clinical values of exosomal MicroRNAs in cancer. Mol Ther Nucleic Acids 2019; 16: 791-804.
[http://dx.doi.org/10.1016/j.omtn.2019.04.027] [PMID: 31163321]
[73]
Falcone G, Felsani A, D’Agnano I. Signaling by exosomal microRNAs in cancer. J Exp Clin Cancer Res 2015; 34(1): 32.
[http://dx.doi.org/10.1186/s13046-015-0148-3] [PMID: 25886763]
[74]
Soung YH, Ford S, Zhang V, Chung J. Exosomes in cancer diagnostics. Cancers (Basel) 2017; 9(1): 8.
[http://dx.doi.org/10.3390/cancers9010008] [PMID: 28085080]
[75]
Liu MX, Liao J, Xie M, et al. miR-93-5p transferred by exosomes promotes the proliferation of esophageal cancer cells via intercellular communication by targeting PTEN. Biomed Environ Sci 2018; 31(3): 171-85.
[PMID: 29673440]
[76]
Liu S, Lin Z, Zheng Z, et al. Serum exosomal microRNA-766-3p expression is associated with poor prognosis of esophageal squamous cell carcinoma. Cancer Sci 2020; 111(10): 3881-92.
[http://dx.doi.org/10.1111/cas.14550] [PMID: 32589328]
[77]
Gao P, Wang D, Liu M, et al. DNA methylation-mediated repression of exosomal miR-652-5p expression promotes oesophageal squamous cell carcinoma aggressiveness by targeting PARG and VEGF pathways. PLoS Genet 2020; 16(4): e1008592.
[http://dx.doi.org/10.1371/journal.pgen.1008592] [PMID: 32343702]
[78]
Salehi M, Sharifi M. Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities. J Cell Physiol 2018; 233(9): 6370-80.
[http://dx.doi.org/10.1002/jcp.26481] [PMID: 29323722]
[79]
Visaggi P, Barberio B, Ghisa M, et al. Modern diagnosis of early esophageal cancer: from blood biomarkers to advanced endoscopy and artificial intelligence. Cancers (Basel) 2021; 13(13): 3162.
[http://dx.doi.org/10.3390/cancers13133162] [PMID: 34202763]
[80]
Fujihara S, Kobara H, Nishiyama N, Hirose K, Iwama H, Masaki T. MicroRNA expression profiles in superficial esophageal squamous cell carcinoma before endoscopic submucosal dissection: A pilot study. Int J Mol Sci 2021; 22(9): 4789.
[http://dx.doi.org/10.3390/ijms22094789] [PMID: 33946439]
[81]
Zarrilli G, Galuppini F, Angerilli V, et al. miRNAs involved in esophageal carcinogenesis and miRNA-related therapeutic perspectives in esophageal carcinoma. Int J Mol Sci 2021; 22(7): 3640.
[http://dx.doi.org/10.3390/ijms22073640] [PMID: 33807389]
[82]
Okuda Y, Shimura T, Iwasaki H, et al. Urinary microRNA biomarkers for detecting the presence of esophageal cancer. Sci Rep 2021; 11(1): 8508.
[http://dx.doi.org/10.1038/s41598-021-87925-1] [PMID: 33879806]
[83]
Chiam K, Wang T, Watson DI, et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J Gastrointest Surg 2015; 19(7): 1208-15.
[http://dx.doi.org/10.1007/s11605-015-2829-9] [PMID: 25943911]
[84]
Qiu ML, Li X, Lin JB, Luo RG, Liu B, Feng Z. Serum exosomal miR-182 upregulation predicts unfavorable prognosis of esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci 2020; 24(10): 5412-8.
[PMID: 32495876]
[85]
Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 2013; 108(3): 644-52.
[http://dx.doi.org/10.1038/bjc.2013.8] [PMID: 23361059]
[86]
Xu J, Yin Z, Yang L, et al. Evidence that dysplasia related microRNAs in Barrett’s esophagus target PD-L1 expression and contribute to the development of esophageal adenocarcinoma. Aging (Albany NY) 2020; 12(17): 17062-78.
[http://dx.doi.org/10.18632/aging.103634] [PMID: 32903213]
[87]
Zhou X, Wen W, Zhu J, et al. A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma. Oncotarget 2017; 8(21): 34468-80.
[http://dx.doi.org/10.18632/oncotarget.16519] [PMID: 28380431]
[88]
Su L-L, Chang XJ, Zhou HD, Hou LB, Xue XY. Exosomes in esophageal cancer: A review on tumorigenesis, diagnosis and therapeutic potential. World J Clin Cases 2019; 7(8): 908-16.
[http://dx.doi.org/10.12998/wjcc.v7.i8.908] [PMID: 31119136]
[89]
Jing Z, Chen K, Gong L. The Significance of exosomes in pathogenesis, diagnosis, and treatment of esophageal cancer. Int J Nanomedicine 2021; 16: 6115-27.
[http://dx.doi.org/10.2147/IJN.S321555] [PMID: 34511909]
[90]
Mao Y, Wang Y, Dong L, et al. Hypoxic exosomes facilitate angiogenesis and metastasis in esophageal squamous cell carcinoma through altering the phenotype and transcriptome of endothelial cells. J Exp Clin Cancer Res 2019; 38(1): 389.
[http://dx.doi.org/10.1186/s13046-019-1384-8] [PMID: 31488217]
[91]
Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential. Front Genet 2012; 3: 56.
[http://dx.doi.org/10.3389/fgene.2012.00056] [PMID: 22529849]
[92]
Yang YC, Liu GJ, Yuan DF, Li CQ, Xue M, Chen LJ. Influence of exosome-derived miR-21on chemotherapy resistance of esophageal cancer. Eur Rev Med Pharmacol Sci 2019; 23(4): 1513-9.
[PMID: 30840273]
[93]
Luo A, Zhou X, Shi X, et al. Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. Oncogene 2019; 38(25): 4990-5006.
[http://dx.doi.org/10.1038/s41388-019-0771-0] [PMID: 30858545]
[94]
He Z, Li W, Zheng T, Liu D, Zhao S. Human umbilical cord mesenchymal stem cells-derived exosomes deliver microRNA-375 to downregulate ENAH and thus retard esophageal squamous cell carcinoma progression. J Exp Clin Cancer Res 2020; 39(1): 140.
[http://dx.doi.org/10.1186/s13046-020-01631-w] [PMID: 32698859]
[95]
Shi S, Huang X, Ma X, Zhu X, Zhang Q. Research of the mechanism on miRNA193 in exosomes promotes cisplatin resistance in esophageal cancer cells. PLoS One 2020; 15(5): e0225290.
[http://dx.doi.org/10.1371/journal.pone.0225290] [PMID: 32369495]
[96]
Guo Y, Ji X, Liu J, et al. Effects of exosomes on pre-metastatic niche formation in tumors. Mol Cancer 2019; 18(1): 39.
[http://dx.doi.org/10.1186/s12943-019-0995-1] [PMID: 30857545]
[97]
Matsumoto Y, Kano M, Murakami K, et al. Tumor-derived exosomes influence the cell cycle and cell migration of human esophageal cancer cell lines. Cancer Sci 2020; 111(12): 4348-58.
[http://dx.doi.org/10.1111/cas.14660] [PMID: 32969511]
[98]
Ni P-Z, He JZ, Wu ZY, et al. Overexpression of Stathmin 1 correlates with poor prognosis and promotes cell migration and proliferation in oesophageal squamous cell carcinoma. Oncol Rep 2017; 38(6): 3608-18.
[PMID: 29039594]
[99]
Yan L, Dong X, Gao J, et al. A novel rapid quantitative method reveals stathmin-1 as a promising marker for esophageal squamous cell carcinoma. Cancer Med 2018; 7(5): 1802-13.
[http://dx.doi.org/10.1002/cam4.1449] [PMID: 29577639]
[100]
Suzuki S, Yokobori T, Altan B, et al. High stathmin 1 expression is associated with poor prognosis and chemoradiation resistance in esophageal squamous cell carcinoma. Int J Oncol 2017; 50(4): 1184-90.
[http://dx.doi.org/10.3892/ijo.2017.3899] [PMID: 28350065]
[101]
Li L, Li X, Wang W, Gao T, Shi Z. UBE2C is involved in the functions of ECRG4 on esophageal squamous cell carcinoma. Biomed Pharmacother 2018; 98: 201-6.
[http://dx.doi.org/10.1016/j.biopha.2017.12.066] [PMID: 29268240]
[102]
Lv J, Zhao HP, Dai K, Cheng Y, Zhang J, Guo L. Circulating exosomal miRNAs as potential biomarkers for Barrett’s esophagus and esophageal adenocarcinoma. World J Gastroenterol 2020; 26(22): 2889-901.
[http://dx.doi.org/10.3748/wjg.v26.i22.2889] [PMID: 32587437]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy